These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 19727211)
21. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation. Gaballa S; Palmisiano N; Alpdogan O; Carabasi M; Filicko-O'Hara J; Kasner M; Kraft WK; Leiby B; Martinez-Outschoorn U; O'Hara W; Pro B; Rudolph S; Sharma M; Wagner JL; Weiss M; Flomenberg N; Grosso D Biol Blood Marrow Transplant; 2016 Jan; 22(1):141-8. PubMed ID: 26415558 [TBL] [Abstract][Full Text] [Related]
22. T cell replete-haploidentical second hematopoietic stem cell transplantation for primary graft failure in pediatric patients with hematologic malignancies. Mochizuki K; Sano H; Akaihata M; Kobayashi S; Waragai T; Ohara Y; Takahashi N; Ito M; Ikeda K; Ohto H; Kikuta A Pediatr Transplant; 2017 Nov; 21(7):. PubMed ID: 28845543 [TBL] [Abstract][Full Text] [Related]
23. Feasibility and Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant High-Dose Cyclophosphamide for Children and Adolescents with Hematologic Malignancies: An AIEOP-GITMO Retrospective Multicenter Study. Berger M; Lanino E; Cesaro S; Zecca M; Vassallo E; Faraci M; De Bortoli M; Barat V; Prete A; Fagioli F Biol Blood Marrow Transplant; 2016 May; 22(5):902-9. PubMed ID: 26860636 [TBL] [Abstract][Full Text] [Related]
24. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Gaballa S; Ge I; El Fakih R; Brammer JE; Kongtim P; Tomuleasa C; Wang SA; Lee D; Petropoulos D; Cao K; Rondon G; Chen J; Hammerstrom A; Lombardi L; Alatrash G; Korbling M; Oran B; Kebriaei P; Ahmed S; Shah N; Rezvani K; Marin D; Bashir Q; Alousi A; Nieto Y; Qazilbash M; Hosing C; Popat U; Shpall EJ; Khouri I; Champlin RE; Ciurea SO Cancer; 2016 Nov; 122(21):3316-3326. PubMed ID: 27404668 [TBL] [Abstract][Full Text] [Related]
25. A novel protocol for haploidentical hematopoietic SCT without in vitro T-cell depletion in the treatment of severe acquired aplastic anemia. Xu LP; Liu KY; Liu DH; Han W; Chen H; Chen YH; Zhang XH; Wang Y; Wang FR; Wang JZ; Huang XJ Bone Marrow Transplant; 2012 Dec; 47(12):1507-12. PubMed ID: 22635243 [TBL] [Abstract][Full Text] [Related]
26. Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents. Yoshihara T; Okada K; Kobayashi M; Kikuta A; Kato K; Adachi N; Kikuchi A; Ishida H; Hirota Y; Kuroda H; Nagatoshi Y; Inukai T; Koike K; Kigasawa H; Yagasaki H; Tokuda K; Kishimoto T; Nakano T; Fujita N; Goto H; Nakazawa Y; Kanegane H; Matsuzaki A; Osugi Y; Hasegawa D; Uoshima N; Nakamura K; Tsuchida M; Tanaka R; Watanabe A; Yabe H Int J Hematol; 2007 Apr; 85(3):246-55. PubMed ID: 17483063 [TBL] [Abstract][Full Text] [Related]
27. Non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from a family donor based on fetomaternal microchimerism in pediatric hematologic malignancies. Ishida H; Morimoto A; Yoshihara T; Kuroda H; Mori K; Fujii N; Tamura S; Hibi S; Todo S; Maruya E; Imashuku S J Pediatr Hematol Oncol; 2004 Jan; 26(1):68-71. PubMed ID: 14707719 [TBL] [Abstract][Full Text] [Related]
28. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors. Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715 [TBL] [Abstract][Full Text] [Related]
29. [A comparison of clinical outcomes between unrelated donor and HLA-haploidentical donor hematopoietic stem cell transplantation]. Chen F; Wu DP; Sun AN; Ma X; Tang XW; Qiu HY; Miao M; Fu ZZ; Jin ZM; Wang Y; Wu XJ; Chen SN; He GS; Wang XL; Xue SL; Zhao Y; Chang WR Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):83-6. PubMed ID: 18681306 [TBL] [Abstract][Full Text] [Related]
30. HLA-mismatched haploidentical transplantation using low-dose anti-thymocyte globulin (ATG: thymoglobulin). Kako S; Akahoshi Y; Harada N; Nakano H; Kameda K; Ugai T; Yamasaki R; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Ashizawa M; Terasako-Saito K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kanda Y Hematology; 2017 Apr; 22(3):129-135. PubMed ID: 27905258 [TBL] [Abstract][Full Text] [Related]
31. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation. Wang JZ; Liu KY; Xu LP; Liu DH; Han W; Chen H; Chen YH; Zhang XH; Zhao T; Wang Y; Huang XJ Transplant Proc; 2011 Jun; 43(5):1928-33. PubMed ID: 21693302 [TBL] [Abstract][Full Text] [Related]
32. [A clinical study of 31 patients with malignant hematopoietic disease treated with non-T cell-depleted HLA-haploidentical hematopoietic stem cell transplantation]. Yang MZ; Yuan YH; Wu DP; Chang WR; He J; Di WY Zhonghua Nei Ke Za Zhi; 2007 Jun; 46(6):482-5. PubMed ID: 17663825 [TBL] [Abstract][Full Text] [Related]
33. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A Biol Blood Marrow Transplant; 2012 Dec; 18(12):1859-66. PubMed ID: 22863841 [TBL] [Abstract][Full Text] [Related]
34. Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China. Gao L; Zhang C; Gao L; Liu Y; Su Y; Wang S; Li B; Yang T; Yuan Z; Zhang X J Hematol Oncol; 2015 Jul; 8():90. PubMed ID: 26208715 [TBL] [Abstract][Full Text] [Related]
35. HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome. Chen Y; Liu K; Xu L; Chen H; Liu D; Zhang X; Shi H; Han W; Wang Y; Zhao T; Wang J; Wang J; Huang X Bone Marrow Transplant; 2010 Aug; 45(8):1333-9. PubMed ID: 20062100 [TBL] [Abstract][Full Text] [Related]
36. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation. Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704 [TBL] [Abstract][Full Text] [Related]
38. A single-center analysis of chronic graft-versus-host disease-free, relapse-free survival after alternative donor stem cell transplantation in children with hematological malignancies. Inagaki J; Fukano R; Noguchi M; Okamura J Int J Hematol; 2017 May; 105(5):676-685. PubMed ID: 28205066 [TBL] [Abstract][Full Text] [Related]
39. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944 [TBL] [Abstract][Full Text] [Related]